Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 10/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.32 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8430006 | 0.93 | ADRB3 (0.36) | RENNMT2NMT1ADRB3PSMB10 | |
| SCHEMBL8248393 | 0.89 | REN (0.36) | RENNMT2NMT1ADRB3ADAM17 | |
| SCHEMBL5869650 | 0.89 | REN (0.36) | RENNMT2NMT1ADRB3ADAM17 | |
| SCHEMBL5870069 | 0.82 | ADRB3 (0.37) | RENNMT2NMT1ADRB3PSMB10 | |
| SCHEMBL8255438 | 0.82 | ADRB3 (0.37) | RENNMT2NMT1ADRB3PSMB10 | |
| SCHEMBL8430320 | 0.81 | NPPA (0.38) | RENPSMB10PSMB2ADAM17ACE | |
| SCHEMBL8430337 | 0.80 | NPPA (0.40) | RENPSMB10PSMB2ACEBCHE | |
| SCHEMBL8430329 | 0.78 | HDAC1 (0.46) | ACESMN1; SMN2 | |
| SCHEMBL8430327 | 0.76 | MEN1 (0.34) | ACE | |
| SCHEMBL8430334 | 0.76 | ACE2 (0.41) | ACESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | REN 7/4885NMT2 441/4885NMT1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.